Sanofi (NASDAQ:SNY) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC trimmed its stake in Sanofi (NASDAQ:SNY) by 1.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 33,918 shares of the company’s stock after selling 367 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Sanofi were worth $1,636,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Synergy Asset Management LLC purchased a new stake in shares of Sanofi in the 4th quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Sunbelt Securities Inc. lifted its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Sierra Ocean LLC acquired a new stake in shares of Sanofi in the fourth quarter worth $44,000. Finally, Versant Capital Management Inc purchased a new position in shares of Sanofi during the fourth quarter valued at $54,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 3.8 %

Shares of NASDAQ SNY opened at $56.52 on Tuesday. The business has a 50 day simple moving average of $51.81 and a 200 day simple moving average of $52.61. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a market cap of $143.44 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.